According to a survey by Bristol-Myers Squibb, approximately 1.85 million new cases of blood cancer will be diagnosed worldwide in 2040, with 918,872 cases of lymphoma, 656,345 cases of leukaemia, and 275,047 cases of myeloma. Furthermore, the survey predicted that by 2040, there will be around 1,100,000 fatalities worldwide owing to blood cancer. Cancer that starts in blood-forming tissue, such as bone marrow, or in immune system cells. Leukemia, lymphoma, and multiple myeloma are examples of blood cancers. Hematologic cancer is another name for it. Drugs including bosulif, busulfan, bosutinib and busulfex are used to treat blood cancer.
Key Growth Drivers:
- Introduction of monoclonal antibodies with safety profile to fight myeloma cells
The expansion of the blood cancer market is fueled by the increasing use of microRNA treatments, the rise of nanomedicine platforms, and the constant introduction of effective and safe therapeutics. With the addition of monoclonal antibodies and histone deacetylase (HDAC) inhibitors to the present therapies array, the medicines market is likely to gain traction. Because of the established clinical profile, clinicians favour biologic therapy with monoclonal antibodies such as darzalex and empliciti.
- Increasing prevalence of blood cancer
The rising prevalence of blood cancer is estimated to enhance the blood cancer market's growth rate. Blood cancer is a form of hematological cancer triggered by certain genetic defects. The disease is treated with medications that modify the immune system and assist in improving the efficacy of chemotherapies, radiation therapies, stem cell transplants, and platelet transfusions.
The report outlines the involvement of key players, including:
- Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.)
Key Market Segmentation
Type (Leukaemia, Lymphoma, Myeloma), Treatment (Medication, Radiation Therapy, Stem Cell Transplant, Others), Diagnosis (Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
The Blood Cancer market report includes the following countries in different regions:
The regions mentioned above encompass a comprehensive coverage of key markets, offering a global perspective on the market landscape. Here's an overview of the regions and the countries they include:
- North America: United States, Canada, and Mexico.
- Europe: Germany, France, United Kingdom, Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, and other European countries.
- Asia-Pacific (APAC): China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and other Asia-Pacific countries.
- Middle East and Africa (MEA): Saudi Arabia, United Arab Emirates (U.A.E), South Africa, Egypt, Israel, and other countries in the Middle East and Africa region.
- South America: Brazil, Argentina, and other countries in South America.
Know More about This Premium Research Report @ https://www.databridgemarketresearch.com/reports/global-blood-cancer-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe.
Contact Us
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com
